IDEXX Laboratories vs Lantheus
IDXX and LNTH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IDXX and LNTH compare
IDEXX Laboratories is the larger company, worth 6.6 times as much as Lantheus ($43.4B against $6.6B).
On earnings, Lantheus is cheaper: it trades at 24.3× trailing earnings, against 38.8× for IDEXX Laboratories.
IDEXX Laboratories grew revenue faster over the last twelve months (12.8% versus 2.3% for Lantheus).
IDEXX Laboratories keeps more of each dollar of sales as profit, with a net margin of 25.0% compared with 17.7% at Lantheus.
IDEXX Laboratories scores higher on the StockData Score (19 against 11 for Lantheus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IDXX | LNTH |
|---|---|---|
| Size and price | ||
| Market cap | $43.4B | $6.6B |
| Share price | $551.21 | $100.46 |
| Change, 1 year | −12.2% | 79.8% |
| Change, 5 years | −13.5% | 247% |
| Beta (5Y) | 1.22 | 0.70 |
| Employees | 11K | 1,193 |
| StockData Score | ||
| Total score | 19 (better) | 11 |
| Valuation score | 2 (better) | 0 |
| Growth score | 5 (better) | 2 |
| Performance score | 6 (better) | 5 |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 38.8× | 24.3× (better) |
| P/S | 9.5× | 4.2× (better) |
| P/B | 26.9× | 5.0× (better) |
| EV/EBITDA | 27.1× | 16.7× (better) |
| P/FCF | 34.6× | – |
| PEG | 2.19 | 0.23 (better) |
| FCF yield | 2.9% | – |
| Fair value | $507.90 | $89.39 |
| Margin of safety | −8.5% (better) | −12.4% |
| Growth | ||
| Revenue growth (TTM) | 12.8% (better) | 2.3% |
| Revenue growth, 5Y average | 9.7% | 35.3% (better) |
| Net income growth (TTM) | 15.6% (better) | 1.6% |
| EPS growth (TTM) | 18.4% (better) | 9.5% |
| EPS growth, 5Y average | 14.3% | – |
| Profitability | ||
| Gross margin | 62.4% (better) | 60.1% |
| Operating margin | 32.0% (better) | 19.4% |
| Net margin | 25.0% (better) | 17.7% |
| FCF margin | 27.5% | – |
| Return on equity | 74.2% (better) | 22.2% |
| Return on invested capital | 63.3% (better) | 19.7% |
| Financial health | ||
| Debt / equity | 0.28 (better) | 0.44 |
| Net debt / EBITDA | 0.16 (better) | −0.06 |
| Interest coverage | 38.6× (better) | 15.3× |
| Current ratio | 1.17 | 3.06 (better) |
| Altman Z-score | 19.89 (better) | 5.47 |
| Piotroski F-score | 8 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | 2.7% | – |
| Shareholder yield | 2.7% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 94.5% | 117% |
| Held by insiders | 0.30% | 2.3% |
| Insider net buying, 12 months | −$37.7M | – |
| Superinvestors holding | 3 | – |
| Short interest, % of float | 2.5% | 5.9% |
Go deeper
- IDXX stock overview
- IDXX income statement
- IDXX valuation and score
- LNTH stock overview
- LNTH income statement
- LNTH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.